

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Tuesday, May 23, 2017 11:16 AM  
**To:** Rizwana Sproule (RSproule@KitePharma.com)  
**Cc:** Nadia Agopyan (NAgopyan@KitePharma.com); 'Alex Babayan'  
**Subject:** Kite Pharma BLA 125643 Statistical Information Request May 23, 2017

**Importance:** High

Dear Dr. Sproule,

You used OVTPRSP2 in dataset RS.xpt as the central review disease response and used it in the efficacy analyses.

- a. Please clarify how this variable differs from others such as OVTPRSP1 or OVRNIN4 in rs.xpt which are also overall disease response assessments and why those are not used as central review disease response.
- b. Please explain how OVTPRSP2 was derived based on the two radiologists' readings and the oncologist assessment.
- c. What does "time point response" mean? Please clarify for variable RSTEST in rs.xpt why some of the test names have "time point response" in it but others do not.

**Please respond by May 24, 2017.**

Thank You

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax: 301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."